Annals of Oncology Advance Access published online on February 14, 2008
Annals of Oncology, doi:10.1093/annonc/mdn020
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil
1 Department of Oncology, Odense University Hospital
2 Department of Oncology, Institute of Clinical Research, University of Southern Denmark, Odense
3 Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev
4 Department of Oncology, Aalborg University Hospital, Aalborg, Denmark
* Correspondence to: Prof. P. Pfeiffer, Department of Oncology, Odense University Hospital, Sdr. Boulevard 29, DK-5000 Odense C, Denmark Tel: +45 6541 1590; Fax: +45 6541 2957; E-mail: Per.Pfeiffer{at}ouh.regionsyddanmark.dk
Background: Standard weekly cetuximab and irinotecan (CetIri) is an effective regimen in heavily pretreated patients with advanced colorectal cancer (ACRC). Inspired by a pharmacokinetic study demonstrating no differences between weekly and biweekly cetuximab, we present the results of 74 consecutive patients treated with biweekly CetIri.
Methods: Biweekly CetIri schedule: cetuximab 500 mg/m2, first course was given as a 120-min infusion followed 1 h later by irinotecan 180 mg/m2 as a 30-min infusion. Subsequent courses of cetuximab were given in 60 min, immediately followed by irinotecan—resulting in an overall treatment time of 90 min.
Results: All patients had ACRC resistant to 5-fluorouracil and irinotecan and 95% to oxaliplatin. Median age was 63 years, median performance status was 0. Median duration of therapy was 4.3 months. Response rate was 25%. Median progression-free survival and overall survival were 5.4 months and 8.9 months, respectively, comparable to own historical controls receiving weekly CetIri. Grade 3–4 toxicity was rare (skin 7%, nail 3%, diarrhoea 10%, fatigue 3%, neutropenia 9%). One patient experienced severe allergic reaction.
Conclusion: Salvage therapy with simplified biweekly CetIri is a convenient, effective and well-tolerated regimen in heavily pretreated patients with ACRC. A confirmatory phase II study is ongoing.
advanced colorectal cancer, biweekly, cetuximab, irinotecan, third-line therapy
Received for publication November 1, 2007. Revision received January 3, 2008. Accepted for publication January 7, 2008.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Tabernero, F. Ciardiello, F. Rivera, E. Rodriguez-Braun, F. J. Ramos, E. Martinelli, M. E. Vega-Villegas, S. Rosello, S. Liebscher, O. Kisker, et al. Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study Ann. Onc., November 25, 2009; (2009) mdp549v1. [Abstract] [Full Text] [PDF]
|
|